TBA-7371

Class: DprE1 inhibitor

Details of activity:	Active against Mycobacterium tuberculosis
Description:	Synthetic compound from scaffold morphing of imidazopyridine compound; no cytotoxicity at 100 uM
Institute where first reported:	Astra Zeneca and TB Alliance
Year first mentioned:	2014
Highest developmental phase:	Phase 2 (NCT04176250)
Development status:	Active (as of 2025)

Chemical structure(s):
Canonical SMILES:	CC1=CN=C2C(=CN(CC3=NC=NC(=C3C)OC)C2=C1)C(=O)NCCO
Isomeric SMILES:	CC1=CC2=C(C(=CN2CC3=C(C(=NC=N3)OC)C)C(=O)NCCO)N=C1
InChI:	InChI=1S/C18H21N5O3/c1-11-6-15-16(20-7-11)13(17(25)19-4-5-24)8-23(15)9-14-12(2)18(26-3)22-10-21-14/h6-8,10,24H,4-5,9H2,1-3H3,(H,19,25)
InChI Key:	VDRYGTNDKXIPSK-UHFFFAOYSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/72792692

External links:
Main Source:	https://journals.asm.org/doi/10.1128/aac.00583-21
Citation:	https://journals.asm.org/doi/10.1128/aac.03233-14